Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D.

Blood. 2001 Sep 15;98(6):1721-6.

2.

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D.

J Clin Oncol. 1997 Jul;15(7):2667-72.

PMID:
9215839
3.

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.

Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP.

Med Oncol. 2001;18(2):99-107. Review.

PMID:
11778765
4.

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.

Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D.

Br J Haematol. 1997 Mar;96(3):617-9.

PMID:
9054672
5.
6.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P.

J Clin Oncol. 2002 Jan 1;20(1):205-13.

PMID:
11773171
7.

Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.

Birhiray RE, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, Brettman L.

Leukemia. 2002 May;16(5):861-4.

8.

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.

Cytotherapy. 2001;3(3):203-10.

PMID:
12171727
9.

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.

Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.

Bone Marrow Transplant. 2000 Jul;26(1):69-76.

10.

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE.

Clin Lymphoma. 2002 Sep;3(2):105-10.

PMID:
12435283
11.

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H.

J Clin Oncol. 1997 Apr;15(4):1567-74.

PMID:
9193354
12.
13.

How I treat prolymphocytic leukemia.

Dearden C.

Blood. 2012 Jul 19;120(3):538-51. doi: 10.1182/blood-2012-01-380139. Epub 2012 May 30.

14.

[Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE.

Tidsskr Nor Laegeforen. 2004 Mar 18;124(6):768-70. Norwegian.

15.

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

McCune SL, Gockerman JP, Moore JO, Decastro CM, Bass AJ, Chao NJ, Long GD, Vredenburgh JJ, Gasparetto C, Adams D, Payne N, Rizzieri DA.

Leuk Lymphoma. 2002 May;43(5):1007-11.

PMID:
12148879
16.

T-cell prolymphocytic leukemia.

Dearden CE.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S239-43. doi: 10.3816/CLM.2009.s.018. Review.

PMID:
19778847
17.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.

Blood. 2000 Oct 1;96(7):2419-25.

18.

Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).

Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerm G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, François S, Peffault de Latour R, Yakoub-Agha I, Mohty M.

Eur J Haematol. 2015 Mar;94(3):265-9. doi: 10.1111/ejh.12430. Epub 2014 Sep 13.

PMID:
25130897
19.

Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.

Döhner H, Ho AD, Thaler J, Stryckmans P, Sonneveld P, de Witte T, Lechner K, Lauria F, Bödewadt-Radzun S, Suciu S, et al.

J Natl Cancer Inst. 1993 Apr 21;85(8):658-62.

PMID:
8468724
20.

Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.

Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, Cairoli R, Pungolino E, Morra E.

Haematologica. 2002 Jul;87(7):695-700; discussion 700.

Supplemental Content

Support Center